AIM ImmunoTech is trading 11.69% up at $0.25, with no clear company-specific catalyst identified for August 17, 2026.

  • Recent second-quarter results, the DURIPANC dosing milestone, and the manufacturing agreement were announced before the current session.
  • The broader market is slightly lower, suggesting the advance appears stock-specific or driven by speculative trading rather than broad market momentum.